Ningbo MedicalSystem Biotechnology Co Ltd Asset Resilience Ratio

Latest as of September 2025: 7.27%

Ningbo MedicalSystem Biotechnology Co Ltd asset resilience ratio. Ningbo MedicalSystem Biotechnology Co Ltd (300439) has an Asset Resilience Ratio of 7.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Ningbo MedicalSystem Biotechnology Co Lt fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥265.90 Million
≈ $38.91 Million USD Cash + Short-term Investments

Total Assets

CN¥3.66 Billion
≈ $534.88 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Ningbo MedicalSystem Biotechnology Co Ltd (2015–2024)

Asset resilience ratio of Ningbo MedicalSystem Biotechnology Co Ltd from 2015 to 2024. This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Read Ningbo MedicalSystem Biotechnology Co Lt (300439) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Ningbo MedicalSystem Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Ningbo MedicalSystem Biotechnology Co Lt total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥265.90 Million 7.27%
Total Liquid Assets CN¥265.90 Million 7.27%

Asset Resilience Insights

  • Limited Liquidity: Ningbo MedicalSystem Biotechnology Co Ltd maintains only 7.27% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Ningbo MedicalSystem Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Ningbo MedicalSystem Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Lonza Group AG
SW:LONN
Diagnostics & Research 3.04%
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
Diagnostics & Research 13.43%
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
Cowealth Medical China Co.Ltd.
SHG:603122
Diagnostics & Research 2.25%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Prodia Widyahusada Tbk PT
JK:PRDA
Diagnostics & Research 7.82%
Scope Fluidics SA
WAR:SCP
Diagnostics & Research 16.51%

Ningbo MedicalSystem Biotechnology Co Ltd Asset Resilience Ratio by Year (2015–2024)

Ningbo MedicalSystem Biotechnology Co Ltd asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Ningbo MedicalSystem Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 4.35% CN¥161.08 Million
≈ $23.57 Million
CN¥3.71 Billion
≈ $542.17 Million
+4.18pp
2023-12-31 0.17% CN¥6.00 Million
≈ $877.99K
CN¥3.49 Billion
≈ $510.58 Million
-2.06pp
2022-12-31 2.24% CN¥80.17 Million
≈ $11.73 Million
CN¥3.58 Billion
≈ $524.40 Million
-0.57pp
2021-12-31 2.80% CN¥100.70 Million
≈ $14.74 Million
CN¥3.59 Billion
≈ $525.80 Million
-2.87pp
2017-12-31 5.67% CN¥242.70 Million
≈ $35.51 Million
CN¥4.28 Billion
≈ $626.09 Million
-4.27pp
2016-12-31 9.95% CN¥340.00 Million
≈ $49.75 Million
CN¥3.42 Billion
≈ $500.20 Million
-10.10pp
2015-12-31 20.04% CN¥290.00 Million
≈ $42.44 Million
CN¥1.45 Billion
≈ $211.71 Million
--
pp = percentage points

About Ningbo MedicalSystem Biotechnology Co Ltd

SHE:300439 China Diagnostics & Research
Market Cap
$577.00 Million
CN¥3.94 Billion CNY
Market Cap Rank
#11173 Global
#3051 in China
Share Price
CN¥10.26
Change (1 day)
+8.11%
52-Week Range
CN¥8.01 - CN¥11.04
All Time High
CN¥49.34
About

Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more